GLP-1 receptor agonist
Semaglutide
Answer
Semaglutide is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 861 registered trials, 348 of them running. Brand names on the FDA label register: Ozempic and Wegovy.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
861 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 108 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 153 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Semaglutide changes on the register. You confirm your address first.
ENFORCEMENT AND OFFICIAL ACTIONS
3 actions by named authorities
Enforcement actions, board positions and payer rules that name Semaglutide, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.
| US-OHenforcement | Ohio Board of Pharmacy, 2026-04-16 During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: e. Semaglutide 10mg, 5 vials;State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraph 2(e) · quoted with the party redacted |
|---|---|
| US-ILmention | Illinois State Board of Pharmacy, 2024-05-07 COMPOUNDING SEMAGLUTIDE The Board reviewed and found helpful a document prepared and published by the North Carolina Board of Pharmacy.Illinois State Board of Pharmacy, Minutes of Open Session, May 7, 2024, Compounding Semaglutide |
| US-NCposition | North Carolina Board of Pharmacy, 2023-04-28 The federal Food Drug & Cosmetic Act prohibits pharmacies from compounding “drug products that are essentially copies of a commercially available drug product.” FD&C Act § 503A(b)(1)(D). In general, then, compounding pharmacies may not compound semaglutide, a commercially available drug product.North Carolina Board of Pharmacy, Statement Concerning Semaglutide Compounding, updated April 28, 2023 |
REGISTERED TRIALS
Newest 10 of 861 trials
| NCT06856291 | Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance completed · register updated 2026-10-02 |
|---|---|
| NCT06977438 | GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward not yet recruiting participants · register updated 2026-10-02 |
| NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New not yet recruiting participants · register updated 2026-10-02 |
| 2022-502922-41-00 | Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 year no status recorded · register updated 2026-10-01 |
| NCT05254314 | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) running, but no longer enrolling · register updated 2026-10-01 |
| NCT06184633 | DUTCH Weight Control in Atrial Fibrillation Study running, but no longer enrolling · register updated 2026-10-01 |
| NCT07112872 | A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes running, but no longer enrolling · register updated 2026-10-01 |
| NCT07249554 | Combination Therapy for Alcohol Use Disorder not yet recruiting participants · register updated 2026-10-01 |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cance not yet recruiting participants · register updated 2026-10-01 |
| 2026-527373-11-00 | SEMAGONA: A randomized four-arm parallel group double-blind double dummy 52-week clinical trial comparing the effects of s.c. Sema no status recorded · register updated 2026-09-30 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.